{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.8","upperLimit":"5.8","value":"5.3"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"2.0","value":"1.7"},{"comment":"The median was not reached as there were not enough events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG003","lowerLimit":"3.1","upperLimit":"4.3","value":"3.7"},{"groupId":"OG004","lowerLimit":"8.6","upperLimit":"10.0","value":"9.2"},{"groupId":"OG005","lowerLimit":"3.3","upperLimit":"3.9","value":"3.6"},{"groupId":"OG006","lowerLimit":"13.1","upperLimit":"13.1","value":"13.1"},{"groupId":"OG007","lowerLimit":"3.0","upperLimit":"3.8","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"3"}],"units":"Participants"}],"description":"PFS will be estimated using the Kaplan-Meier curve and reported along with a 95% confidence interval. PFS is defined as the duration of time from the date of study enrollment until time of disease relapse, disease progression, or death, whichever occurs first measured by the Response Evaluation Criteria in Lymphoma (RECIL) 2017 criteria. Progressive disease is \\>20% increase in the sum of longest diameters of target lesions. Disease relapse is defined as new areas of disease or \\>50% increase in growth of target lesion.","dispersionType":"95% Confidence Interval","groups":[{"description":"T-cell Malignancies, Dose Escalation, Arm 1, Dose Level -1 Arm 1, Dose Level -1: Lenalidomide 2.5 mg Day 1-10 (7 days lead in for first cycle); CC-486 (5azacitidine) 200 mg by mouth (PO Day) 1 to 10; Romidepsin 12 mg/m\\^2 intravenous (IV) Day 1 and day 10; Dexamethasone 40 mg PO Day 1 and day 10. Relapsed/refractory mature T cell malignancies for determination of maximum tolerated dose (MTD).","id":"OG000","title":"Arm 1, Cohort 1, Dose Level -1, Dose Escalation Lenalidomide"},{"description":"T-cell Malignancies, Dose Escalation, Arm 1, Dose Level 1 Arm 1, Dose Level 1: Lenalidomide 5 mg Day 1-10 (7 days lead in for first cycle); CC-486 (5azacitidine) 300 mg by mouth (PO Day) 1 to 10; Romidepsin 12 mg/m\\^2 intravenous (IV) Day 1 and day 10; Dexamethasone 40 mg PO Day 1 and day 10. Relapsed/refractory mature T cell malignancies for determination of maximum tolerated dose (MTD).","id":"OG001","title":"Arm 1, Cohort 1, Dose Level 1, Dose Expansion Lenalidomide"},{"description":"T-cell Malignancies, Dose Escalation, Arm 1, Dose Level 2 Arm 1, Dose Level 2: Lenalidomide 10 mg Day 1-10 (7 days lead in for first cycle); CC-486 (5azacitidine) 300 mg by mouth (PO Day) 1 to 10; Romidepsin 12 mg/m\\^2 intravenous (IV) Day 1 and day 10; Dexamethasone 40 mg PO Day 1 and day 10. Relapsed/refractory mature T cell malignancies for determination of maximum tolerated dose (MTD).","id":"OG002","title":"Arm 1, Cohort 1, Dose Level 2, Dose Escalation Lenalidomide"},{"description":"T-cell Malignancies, Dose Escalation, Arm 1, Dose Level 3 Arm 1, Dose Level 3: Lenalidomide 15 mg Day 1-10 (7 days lead in for first cycle); CC-486 (5azacitidine) 300 mg by mouth (PO Day) 1 to 10; Romidepsin 12 mg/m\\^2 intravenous (IV) Day 1 and day 10; Dexamethasone 40 mg PO Day 1 and day 10. Relapsed/refractory mature T cell malignancies for determination of maximum tolerated dose (MTD).","id":"OG003","title":"Arm 1, Cohort 1, Dose Level 3 Dose Escalation"},{"description":"T-cell Malignancies, Dose Escalation, Arm 1, Dose Level 4 Arm 1, Dose Level 4: Lenalidomide 20 mg Day 1-10 (7 days lead in for first cycle); CC-486 (5azacitidine) 300 mg by mouth (PO Day) 1 to 10; Romidepsin 12 mg/m\\^2 intravenous (IV) Day 1 and day 10; Dexamethasone 40 mg PO Day 1 and day 10. Relapsed/refractory mature T cell malignancies for determination of maximum tolerated dose (MTD).","id":"OG004","title":"Arm 1, Cohort 1, Dose Level 4, Dose Escalation Lenalidomide"},{"description":"T-cell Malignancies, Dose Expansion, Arm 2, Dose Level 2 Arm 2, Dose Level 2: Lenalidomide by oral intake at maximum tolerated dose (MTD) on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, Romidepsin at 12 mg/m\\^2 by intravenous (IV) infusion on Day 1 and day 10; and Dexamethasone at 40 mg by oral intake on days 1 and 10 of each cycle. Relapsed/refractory mature T cell malignancies enrolled after maximum tolerated dose (MTD) is determined.","id":"OG005","title":"Arm 2, Cohort 2, Dose Level 2, Dose Expansion Lenalidomide"},{"description":"T-cell Malignancies, Dose Expansion, Arm 2, Dose Level 4 Arm 2, Dose Level 4: Lenalidomide by oral intake at maximum tolerated dose (MTD) Day 1-10 (7 days lead in for first cycle); CC-486 (5azacitidine) 300 mg by mouth (PO Day) 1 to 10; Romidepsin 12 mg/m\\^2 intravenous (IV) Day 1 and day 10; Dexamethasone 40 mg PO Day 1 and day 10. Relapsed/refractory mature T cell malignancies enrolled after maximum tolerated dose (MTD) is determined.","id":"OG006","title":"Arm 2, Cohort 2, Dose Level 4, Dose Expansion Lenalidomide"},{"description":"T-cell Malignancies, Dose Expansion, Arm 3, Dose Level 4 Arm 3, Dose Level 4: Lenalidomide 20 mg maximum tolerated dose (MTD) by oral intake at on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, Romidepsin at 12 mg/m\\^2 by intravenous (IV) infusion on Day 1 and day 10; and Dexamethasone at 40 mg by oral intake on days 1 and 10 of each cycle. Relapsed/refractory mature T cell malignancies enrolled after maximum tolerated dose (MTD) is determined.","id":"OG007","title":"Arm 3, Cohort 2, Dose Level 4, Dose Expansion Lenalidomide"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to a median of 13.1 months","title":"Progression-free Survival (PFS) in Months Reported Along With a 95% Confidence Interval","type":"SECONDARY","unitOfMeasure":"Months"}